Overview
Clairvest has acquired Boca Biolistics to accelerate the growth of the company’s infectious disease and oncological biobanking capabilities.
Significance
Precision medicine has blossomed into one of the highest growth market segments of the healthcare industry, valued at ~$60 billion today and projected to grow to $800 billion by 2028. Biobanks, and the genetic insights they provide, form an essential bridge from traditional to precision medicine and its promise of new, more effective therapies tailored to precise genomic signatures.
Founded in 2007, Boca Biolistics (Boca) is a leading clinical research organization (CRO) and biomaterials company focused on the procurement, storage, and sale of human biological samples (specializing in infectious diseases and oncology) used for clinical trials and diagnostic development. Boca has a strong reputation as a trusted vendor in the industry and sources samples from its proprietary network of collection sites internationally. The Company also offers in-house analytical laboratory testing and characterization services for internal and third-party samples.
Boca’s high growth profile and differentiated positioning within the biobanking industry made it the ideal acquisition for Clairvest’s ongoing multi-year domain effort in the life sciences industry.
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
